The FDA granted priority review to rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.
A recent study shows the importance of information regarding adverse events of cancer treatment for prospective patients.
When treatment decisions were made using a prostate genomic classifier after radical prostatectomy in men with prostate cancer, patient outcomes significantly improved.
Single dose radiotherapy may be as effective as 5 doses for patients with spinal canal compression from metastatic cancer.
Researchers indicated that among men age ≥66 with prostate cancer, organ transplant is associated with higher overall mortality but no observable difference in prostate cancer-specific mortality.
The FDA approved enzalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.
Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.
Myovant announced that their phase III HERO study of relugolix met its primary efficacy end point and all 6 secondary endpoints in men with advanced prostate cancer.
An international study of prostate cancer clinical trials discovered that opioid use appears to differ by region, implying that a variability should be considered.
Fewer biopsies among men receiving antidiabetic medications may explain the lower prostate cancer risk in men with diabetes.